The short version of glucagon receptor fits in a sentence. The long version — which is the one that helps — is below.
Reviewed 2026-04-29. Anything still debated is marked as such rather than presented as settled.
Retatrutide is an investigational synthetic peptide that acts on three receptor targets at once: glucose-dependent insulinotropic polypeptide, glucagon-like peptide-1, and glucagon. It is developed by Eli Lilly and appears in the literature and in trial registries under the code LY3437943. The molecule belongs to a class of engineered peptides designed to resist rapid breakdown and permit infrequent subcutaneous administration. No regulatory agency has approved it for clinical use, and all available human data come from controlled trials rather than from routine practice.
The intended pharmacology combines three signals in one molecule. GLP-1 receptor activation reduces appetite and slows gastric emptying, effects already exploited by approved incretin-based therapies. GIP receptor engagement is associated with improved insulin sensitivity and with direct effects on adipose tissue, although how much it contributes to overall outcomes is still debated. Glucagon receptor agonism raises energy expenditure and supports hepatic lipid handling, a mechanism that also tends to increase glucose output. The triple profile is hypothesized to produce a larger metabolic effect than single or dual agonism, but the relative weight of each receptor in humans is not settled.
Human evidence remains limited to controlled studies. A phase 2 trial in adults with obesity reported large, dose-dependent reductions in body weight over 48 weeks, with gastrointestinal events as the most frequently recorded adverse effect. Phase 3 programs designated TRIUMPH, for obesity, and TRANSCEND, for type 2 diabetes, are intended to confirm efficacy and to characterize safety in larger populations. Related studies are examining conditions such as knee osteoarthritis in people with obesity and metabolic liver disease. Open questions include long-term tolerability, effects on lean mass, and what happens after treatment is stopped.
冻干粉通常在低温环境下保存，复溶之后需要按指定条件在较短时间内使用。反复冻融和剧烈振荡可能促进聚集，低吸附容器则能减少多肽在管壁上的损失。批号、日期与处理条件的完整记录，是后续复核与问题追溯的基础。
供应环节涉及来源核实与文件审核两类工作。分析证书、批次记录以及第三方检测报告构成常见的可追溯材料。来源不清的样品很难确认身份与纯度，因此核实步骤在实际操作中具有明确意义。缺少方法细节的报告通常无法复核。
| Property | Value | Notes |
|---|---|---|
| Compound class | Synthetic triple-agonist peptide | Single linear chain carrying three receptor activities |
| Reported molecular weight | Approximately 4731 Da | Calculated from the published sequence; sources vary slightly |
| Appearance | White to off-white lyophilized powder | Typical of purified research-grade peptides |
| Solubility | Freely soluble in water; poorly soluble in nonpolar solvents | Dissolves in aqueous buffer near neutral pH |
| Storage of dry powder | -20 °C or below, desiccated, protected from light | Avoid repeated temperature cycling |
Retatrutide is a synthetic peptide developed as a single molecule that activates three distinct hormone receptors: GLP-1, GIP, and glucagon. The compound carries the internal designation LY3437943 and was engineered by modifying the backbone of glucose-dependent insulinotropic polypeptide. Its sequence incorporates non-natural amino acids and a fatty acid side chain that extends circulation time. The triple-agonist design aims to combine appetite suppression, improved insulin response, and increased energy expenditure in one agent. Published reports describe it as an investigational product rather than an approved medicine.
Each receptor contributes a different physiological effect. Activation of the GLP-1 receptor slows gastric emptying and reduces appetite signaling in the brain. GIP receptor activity influences insulin secretion and lipid handling, while glucagon receptor stimulation raises energy use and fat oxidation. Combining these pathways is intended to produce weight loss beyond what single- or dual-receptor agonists achieve. Researchers attribute the observed potency to simultaneous engagement of all three targets, though the exact contribution of each receptor to overall effect remains under investigation.
开发进程从早期单次和多次给药研究推进至大规模后期试验。公开报告显示，参与者在体重和相关代谢指标上出现变化，但完整数据需经同行评审并接受独立复核。试验设计通常包括随机、双盲和对照设置，以区分药物效应与行为干预。监管提交和标签范围尚未确定；长期维持效果与心血管结局仍是开放问题。
与仅靶向单一受体的同类药物相比，瑞他鲁肽增加胰高血糖素受体成分，理论上可提高能量消耗并改变脂肪分布。临床中观察到的体重变化是否主要来自该额外机制，目前尚无定论。胃肠道反应是该类药物常见不良事件，试验中通过剂量递增和监测进行管理。停药后体重反弹、个体差异和长期耐受性仍需更多数据。
Several questions about the compound remain unresolved. The durability of weight reduction after treatment stops, the frequency of gastrointestinal side effects, and the long-term cardiovascular profile are topics of ongoing study. Regulatory submissions and phase 3 trial outcomes have not been fully reported in the public literature. Because most available data come from controlled trials rather than general-population use, conclusions about effectiveness outside study settings are provisional. The distinction between established findings and open questions matters when interpreting early coverage of the drug.
Retatrutide is an investigational peptide developed by a pharmaceutical company as a multi-receptor agonist for treating obesity and type 2 diabetes. The compound emerged from research into gut-hormone analogues that act on several receptors simultaneously rather than on a single target. Early preclinical work examined how combined activity at three distinct receptors might produce greater metabolic effects than single-receptor compounds. Published phase 2 results have described substantial reductions in body weight among participants, although the compound remains unapproved in most jurisdictions as of the mid-2020s.
Pharmacologically, retatrutide acts as a triple agonist at the glucagon-like peptide-1 receptor, the glucose-dependent insulinotropic polypeptide receptor, and the glucagon receptor. Activation of the first two receptors is associated with improved insulin secretion and reduced appetite. The glucagon receptor component is thought to increase energy expenditure, a mechanism that distinguishes this molecule from dual-agonist compounds. Researchers continue to investigate how the three activities interact and whether the combined profile offers advantages that justify additional clinical testing.
=== Marriage and family === In 1937, Dorothy Crowfoot married Thomas Lionel Hodgkin, an historian's son, who was then teaching an adult-education class in mining and industrial communities in the north of England after he resigned from the Colonial Office. He was an intermittent member of the Communist Party and later wrote several major works on African politics and history, becoming a well-known lecturer at Balliol College in Oxford. As his health was too poor for active military service, he continued working throughout World War II, returning to Oxford on the weekends, where his wife remained working on penicillin. The couple had three children: Luke (1938 – October 2020), Elizabeth (born 1941) and Toby (born 1946). The oldest son, Luke, became a mathematics instructor at the new University of Warwick. Their daughter, Elizabeth, followed her father's career as a historian. Their younger son, Toby, studied botany and agriculture. Overall, Thomas Hodgkin spent extended periods of time in West Africa, where he was an enthusiastic supporter and chronicler of the emerging postcolonial states. Thomas Hodgkin died in Greece on 25 March 1982.
Attacking with fresh troops, the 82nd broke through the Hindenburg line on 15 October. On 18 October, the 82nd Division relieved the 78th division at Champigneulle. Three days later it advanced to the Ravin aux Pierres. On 31 October, the 82nd, except the artillery, was relieved by the 77th Division and the 80th Division, and assembled in the Argonne Forest to regroup. On 10 November, it moved again to training areas in Bourmont, where it remained until the Armistice of 11 November 1918.
=== Photoconductors === Amorphous selenium (α-Se) thin films have found application as photoconductors in flat-panel X-ray detectors. These detectors use amorphous selenium to capture and convert incident X-ray photons directly into electric charge. Selenium has been chosen for this application among other semiconductors owing to a combination of its favorable technological and physical properties:
Sources: en.wikipedia.org
Fluoroscopy and angiography are special applications of X-ray imaging, in which a fluorescent screen and image intensifier tube is connected to a closed-circuit television system. This allows real-time imaging of structures in motion or augmented with a radiocontrast agent. Radiocontrast agents are usually administered by swallowing or injecting into the body of the patient to delineate anatomy and functioning of the blood vessels, the genitourinary system, or the gastrointestinal tract (GI tract). Two radiocontrast agents are presently in common use. Barium sulfate (BaSO4) is given orally or rectally for evaluation of the GI tract. Iodine, in multiple proprietary forms, is given by oral, rectal, vaginal, intra-arterial, or intravenous routes. These radiocontrast agents strongly absorb or scatter X-rays, and in conjunction with the real-time imaging, allow demonstration of dynamic processes, such as peristalsis in the digestive tract or blood flow in arteries and veins. Iodine contrast may also be concentrated in abnormal areas more or less than in normal tissues and make abnormalities (tumors, cysts, inflammation) more conspicuous. Additionally, in specific circumstances, air can be used as a contrast agent for the gastrointestinal system, and carbon dioxide can be used as a contrast agent in the venous system; in these cases, the contrast agent attenuates the X-ray radiation less than the surrounding tissues.
Mistaken diagnoses are sometimes very serious problems as physicians concentrate on treatment after a diagnosis is reached, not retracing the diagnostic analysis. Ideally, diagnoses are always correct, but disease variations are such that they are sometimes in error. In the case of diabetes, the tests are very clear. If you do not have high blood glucose at times (e.g., when fasting), you should not be diagnosed as diabetic, though perhaps as "prediabetic". Every one has higher glucose levels for one or two hours after eating food which contains some types of carbohydrates. Dialysis providing kidney function artificially. This requires an artificial kidney (a dialysis machine) and relatively long periods hooked up to the machine every few days. It is not equivalent to a working kidney, but is sufficient to maintain life, sometimes for extended periods. Diastolic blood pressure See: Blood pressure. Diet plan See: Meal plan. Dietitian An expert in nutrition who helps people with special health needs plan the kinds and amounts of foods to eat. In the US, a registered dietitian (R.D.) has special training and experience. The health care team for diabetes should ideally include a dietitian, preferably an R.D. Dilated pupil examination A necessary part of an examination for diabetic eye disease. Special drops are used to enlarge the pupils, enabling the doctor to view the retina at the back of the eye for damage. See funduscopy. Distal sensory neuropathy See: Peripheral neuropathy.
A megakaryoblast (from mega- 'large', karyo- 'cell nucleus' and -blast 'precursor cell') is a precursor cell to a promegakaryocyte. During thrombopoiesis, the promegakaryocyte matures into the form of a megakaryocyte. From the megakaryocyte, platelets are formed. The megakaryoblast is the beginning of the thrombocytic series or platelet forming series. Megakaryoblasts typically have a large oval-shaped nucleus or a nucleus that is lobed with many nuclei. The megakaryoblast resembles the myeloblast or lymphoblast morphologically; however the megakaryoblast varies in phenotype and the structure viewed with electron microscopy. Increased amounts of megakaryoblasts in the bone marrow may indicate a disease state. An example of this is acute megakaryoblastic leukemia, which occurs when the level of megakaryoblasts in the bone marrow exceeds 20%.
Sources: en.wikipedia.org
It is an investigational peptide that activates three hormone receptors: GIP, GLP-1 and glucagon. It is being studied mainly for obesity and type 2 diabetes, and it is not approved for any clinical use. Published information comes from controlled trials rather than from general practice.
No. As of the most recent public information it remains investigational in every jurisdiction. Material sold under this name outside trials is a research chemical, not an approved medicine. Current status should always be checked against regulator notices.
Dual agonists act on two receptors, usually GIP and GLP-1. Retatrutide adds glucagon receptor activity, which is associated with increased energy expenditure. Whether that third component adds clinically meaningful benefit over dual agonism remains an open question.
常用质谱测定分子量，再结合肽图或序列分析验证一级结构。单一检测手段一般难以排除结构相近的类似物。多种方法相互印证更为可靠。